Fox Run Management L.L.C. Has $589,000 Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Fox Run Management L.L.C. lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 93.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 62,570 shares of the biopharmaceutical company’s stock after acquiring an additional 30,162 shares during the period. Fox Run Management L.L.C.’s holdings in Amicus Therapeutics were worth $589,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. HealthInvest Partners AB grew its position in Amicus Therapeutics by 18.6% in the fourth quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company’s stock valued at $3,076,000 after acquiring an additional 51,368 shares during the period. Wellington Management Group LLP increased its position in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Tempus Wealth Planning LLC bought a new position in Amicus Therapeutics during the 4th quarter valued at about $259,000. Neo Ivy Capital Management acquired a new position in Amicus Therapeutics in the third quarter valued at about $702,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in Amicus Therapeutics by 35.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company’s stock worth $2,850,000 after buying an additional 79,602 shares during the last quarter.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $8.69 on Tuesday. Amicus Therapeutics, Inc. has a 52 week low of $8.55 and a 52 week high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -48.28, a PEG ratio of 1.51 and a beta of 0.69. The firm has a fifty day moving average of $9.34 and a two-hundred day moving average of $10.04.

Analysts Set New Price Targets

Several brokerages have recently commented on FOLD. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.